title: Reply to C.d. Atkins and a. Avan et Al.
authors.affiliation: Mayo Clinic, Rochester, MN cloprinzi@mayo.edu.
authors.forename: Charles L
authors.initials: CL
authors.lastname: Loprinzi
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Rui
authors.initials: R
authors.lastname: Qin
authors.affiliation: Mayo Clinic, Rochester, MN.
authors.forename: Axel
authors.initials: A
authors.lastname: Grothey
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D002118:Calcium / Q000627:therapeutic use*; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008274:Magnesium / Q000627:therapeutic use*; D008297:Male; D009944:Organoplatinum Compounds / Q000009:adverse effects*; D010523:Peripheral Nervous System Diseases / Q000517:prevention & control*
chemical_list: D009944:Organoplatinum Compounds; D008274:Magnesium; D002118:Calcium